Pathogenesis of follicular thymic hyperplasia associated with rheumatoid arthritis
- PMID: 35147259
- PMCID: PMC9304286
- DOI: 10.1111/pin.13212
Pathogenesis of follicular thymic hyperplasia associated with rheumatoid arthritis
Abstract
Lymphoproliferative disorders may occur in patients with rheumatoid arthritis (RA) who are treated with methotrexate. However, follicular thymic hyperplasia (FTH) associated with RA (FTH-RA) is generally not considered a lymphoproliferative disorder. To investigate the pathogenesis of FTH-RA, we examined 12 cases of FTH involving thymic enlargement, four of FTH involving RA and eight of FTH involving myasthenia gravis (MG). Increased numbers and larger germinal center (GC) size were observed in FTH-RA group. The percentage of distorted GCs was 13.3% in FTH-RA group and 3.25% in FTH associated with MG (FTH-MG) group. A greater meshwork of follicular dendritic cells was observed in the GCs of FTH-RA group. Positive indices of CD27+ cells and PD-1+ cells per GC in FTH-RA group were significantly higher than those in FTH-MG group, though positive indices of CD68+ cells and CD163+ cells were similar. Myoid cell proliferation, as evaluated by α-SMA, tenascin-C, and l-caldesmon expression, was significantly increased in the FTH-RA group compared with the FTH-MG group. These results suggest that FTH should be considered in patients with RA treated with methotrexate. The pathogenesis of FTH-RA includes GC expansion and increased numbers of memory B cells, follicular helper T cells, and myoid cells, indicating humoral immunity activation.
Keywords: follicular helper T-cell; follicular thymic hyperplasia; germinal center; humoral immunity; memory B-cell; myasthenia gravis; myoid cell; rheumatoid arthritis.
© 2022 The Authors. Pathology International published by Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
All authors declare that there are no conflict of interests.
Figures
References
-
- Gaulard P, Swerdlow SH, Harris N,L, Sundström C, Jaffe ES Other iatrogenic immunodeficiency‐associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Harald S et al editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4 ed. Lyon: International Agency for Research on Cancer (IARC); 2017. p. 462–4.
-
- Kurita D, Miyoshi H, Ichikawa A, Kato K, Imaizumi Y, Seki R, et al. Methotrexate‐associated lymphoproliferative disorders in patients with rheumatoid arthritis: Clinicopathologic features and prognostic factors. Am J Surg Pathol. 2019;43:869–84. - PubMed
-
- Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease‐modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99. - PubMed
-
- Weissferdt A, Moran CA. Thymic hyperplasia with lymphoepithelial sialadenitis (LESA)‐like features: a clinicopathologic and immunohistochemical study of 4 cases. Am J Clin Path. 2012;138:816–22. - PubMed
-
- Mlika M, Ayadi‐Kaddour A, Marghli A, Ismail O, Kilani T, El Mezni F. True thymic hyperplasia versus follicular thymic hyperplasia: a retrospective analysis of 13 cases. Pathologica. 2009;101:175–9. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
